Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?

European Archives of Psychiatry and Clinical Neuroscience

Volumn 258, Issue 6, 2008, Pages 319-323

  Önder, Emin ^a   Tural, Ümit ^a   Gökbakan, Mehmet ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

Co administration; Fluoxetine; Gabapentin; OCD

Indexed keywords

ALPRAZOLAM; FLUOXETINE; GABAPENTIN;

ADD ON THERAPY; ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; FEMALE; GABAERGIC SYSTEM; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; MALE; MONOTHERAPY; MORNING DOSAGE; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SYMPTOMATOLOGY; XEROSTOMIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AMINES; ANALYSIS OF VARIANCE; ANTI-ANXIETY AGENTS; CYCLOHEXANECARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 50249184141     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00406-007-0798-z     Document Type: Article

References (36)

1. Baxter LR (2001) Functional imaging of brain systems mediating obsessive-compulsive disorder. In: Charney DS, Nestler EJ, Bunny BS (eds) Neurobiology of mental illness. Oxford University Press, New York, pp 534-547
2. 2δ calcium channel subunit from porcine cerebral cortex J Biol Chem 273 25458 25465
3. G Chouinard L Beauclair MC Bélanger 1998 Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders (Letter) Can J Psychiatry 43 305
4. G Cora-Locatelli BD Greenberg J Martin DL Murphy 1998 Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder (Letter) J Clin Psychiatry 59 480 481
5. G Cora-Locatelli BD Greenberg J Martin DL Murphy 1998 Valproate monotherapy in an SRI-intolerant OCD patient J Clin Psychiatry 59 82
6. V Coric S Taskiran C Pittenger S Wasylink D Mathalon G Valentine J Saksa YT Wu R Gueorguieva G Sanacora RT Malison JH Krystal 2005 Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial Biol Psychiatry 58 424 428
7. AS Çilli M Telcioǧlu R AşkIn N Kaya S Bodur R Kucur 2004 12 month prevalence of obsessive-compulsive disorder in Konya, Turkey Compr Psychiatry 45 367 374
8. A ÇorapçIoǧlu Ö Aydemir M YIldIz AE DanacI E Köroǧlu 1999 DSM-IV Eksen I bozukluklarI için yapIlandIrIlmIş klinik görüşmenin Türkçe'ye uyarlanmasI güvenirlik çalIşmasI. (Adaptation to Turkish and reliability of Structured Clinical Interview for DSM-IV, Axis I disorders) İlaç ve Tedavi Dergisi 12 233 236 [Turkish]
9. JA Deltito 1994 Valproate pretreatment for the difficult-to-treat patient with OCD (Letter) J Clin Psychiatry 55 500
10. F De-Paris JV Busnello JB Salgeuiro J Quevedo I Izguierdo F Kapczincki 2000 The anticonvulsant compund gabapentin possesses anxiolytic but not amnesic effects in rats Behav Pharmacol 11 169 173
11. F De-Paris MK Sant'Anna MRM Vianna T Barichello J Busnello 2003 Effects of gabapentin on anxiety induced by simulated public speaking J Psychopharmacol 17 184 188
12. Doǧan O, Gülmez H, Ketenoǧlu C, Kiliçkap Z, Özbek H, Akyüz G (1995) Ruhsal bozukluklarin epidemiyolojisi [Epidemiology of psychiatric disorders]. Dilek Matbaasi, Sivas, pp 50-52 [Turkish]
13. Erol N, KIlIç C, Ulusoy M Keçeci M, Şimşek Z (1997) Türkiye Ruh SaǧlIǧI Profili [Mental health profile of Turkey main report. Ministry of Health Publications]. SaǧlIk BakanlIǧI Temel SaǧlIk Hizmetleri Genel Müdürlü ǧü, Ankara [Turkish]
14. First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structured clinical interview for DSM-IV clinical version (SCID-I/CV). American Psychiatric Press, Washington, DC
15. 2δ subunit of a calcium channel J Biol Chem 271 5768 5776
16. WK Goodman LH Price SA Rasmussen C Mazure RL Fleischmann CL Hill GR Heninger DS Charney 1989 The Yale-Brown obsessive-compulsive scale I: development, use, and reliability Arch Gen Psychiatry 46 1006 1111
17. Guy W (1976) Early clinical drug evaluation until assessment manual for psychopharmacology. Publication ADM 76-338. US Department of Health, Education and Welfare, Washington, DC
18. O Honmou AA Oyelese JD Kocsis 1995 The anticonvulsant gabapentin enhances promoted release of GABA in hippocampus: a field potential analysis Brain Res 692 273 277
19. Y Iwata Y Kotani R Hoshino N Takei M Iyo N Mori 2000 Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder J Clin Psychiatry 61 528 529
20. MA Jenike 2004 Obsessive-compulsive disorder N Engl J Med 350 259 265
21. MA Jenike AW Brotman 1984 The EEG in obsessive-compulsive disorder J Clin Psychiatry 45 122 124
22. MR Johnson RB Lydiard 1995 The neurobiology of anxiety disorders Psychiatr Clin North Am 18 681 725
23. Karamustafalioǧlu OK, Üçişik AM, Ulusoy M, Erkmen H (1993) Yale-Brown Obsesyon Kompülsiyon Derecelendirme Ölçeǧinin geçerlik ve güvenirlik çalişmasi [Validity and reliability study of Yale-Brown Obsession-Compulsion Scale]. Poster presented at 29th Congress of National Psychiatry Procedings book, 1993, p 86 [Turkish]
24. İ KIrpInar A Çayköylü M Kuloǧlu 1994 Erzurum'da ruh saǧlIǧI birimlerine ulaşIm yollarI [pathways to psychiatric units in Erzurum] Turk Psikiyatri Derg 5 175 181 [Turkish]
25. TC Kumar S Khanna 2000 Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder Aust N Z J Psychiatry 34 527 528
26. PJ Magistretti L Pellerin DL Rothman RG Shulman 1999 Energy on demand Science 283 496 497
27. MJ McGrath KM Campbell CR Parks FH Burton 2000 Glutamatergic drugs exacerbate symptomatic behavior in transgenic model of comorbid Tourette's syndrome and obsessive compulsive disorder Brain Res 877 23 30
28. AC Pande JR Davidson JW Jefferson CA Janney DJ Katzelnick RH Weisler JH Greist SM Sutherland 1999 Treatment of social phobia with gabapentin: a placebo-controlled study J Clin Psychopharmacol 19 341 348
29. AC Pande MH Pollack J Crockatt M Greiner G Chouinard RB Lydiard CB Taylor SR Dager T Shiovitz 2000 Placebo-controlled study of gabapentin treatment of panic disorder J Clin Psychopharmacol 20 467 71
30. MH Pollack J Matthews EL Scott 1998 Gabapentin as a potential treatment for anxiety disorders (letter) Am J Psychiatry 155 992 993
31. DR Rosenberg FP MacMaster MS Keshavan KD Fitzgerald CM Stewart GJ Moore 2000 Decrease incaudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine J Am Acad Child Adolesc Psychiatry 39 1096 1103
32. K Schruers K Koning J Luermans MJ Haack E Griez 2005 Obsessive-compulsive disorder: a critical review of therapeutic perspectives Acta Psychiatr Scand 111 261 271
33. L Singh MJ Field P Ferris JC Hunter RJ Oles RG Williams GN Woodruff 1996 The antiepileptic agent gabapentin (Neurontin) posesses anxiolytic-like and antinociceptive action that are reversed by D-serine Psychopharmacology 127 1 9
34. N Suman-Chauhan L Webdale DR Hill JC Hunter RJ Oles RG Williams GN Woodruff 1993 Characterisation of [3H] gabapentin binding to a novel site in rat brain: homogenate binding studies Eur J Pharmacol 244 293 301
35. M Van Ameringen C Mancini B Patterson M Bennett 2006 Topiramate augmentation in treatment resistant obsessive-compulsive disorder: a retrospective, open-label case series Depress Anxiety 23 1 5
36. Zohar J, Fineberg N (2001) Practical pharmacotherapy. In: Fineberg N, Marazitti D, Stein D (eds) Obsessive-compulsive disorder: a practical guide. Martin Dunitz, London, pp 103-117